Navigation Links
NEWSLETTER: Antibody Fragment Production Breakthrough with 2nd Generation EBA
Date:5/12/2009

Hamburg, Germany and Copenhagen, Denmark, May 12th, 2009 / b3c newswire / – Richter-Helm BioLogics GmbH & Co. KG announces today a technological breakthrough in the field of purification of antibody fragments from an E. coli expression system. Richter-Helm BioLogics has finalized the downstream process for Phase III clinical trial material using 2nd Generation Expanded Bed Adsorption (EBA) technology developed by the Danish biotech company Upfront Chromatography A/S.

Having conducted a series of tests, Richter-Helm has discovered significant advantages of 2nd Generation EBA over the latest, alternative chromatographic methods. A 60% increase in yield was observed using direct capture.  The simplified process is less likely to cause processing problems.  The processing time to take product from homogenate to clarified, partially purified material was reduced to one working day, decreasing the possibility of product degradation.  The volume of buffers required to perform clarification and capture was reduced significantly, effecting cost of manufacture.

Upfront’s innovation lay in the usage of higher density adsorbents and the proprietary design of an operational system which provides increased flow rates and is free from clogging and channel formation.

Rhobust® has improved Richter-Helm’s offering to customers operating with microbial derived products, providing a superior downstream process for clinical manufacturing. Richter-Helm embraced this technology under tight timelines and cost pressures and has been rewarded with a superior downstream offering in the CMO market.

The Rhobust® universal processing platform from Upfront Chromatography enables customers to efficiently capture and purify monoclonal antibodies, therapeutic proteins and other biomolecules directl
'/>"/>

b3c newswire

1

GOOD

Page: 1 2

Related biology news :

1. Novel antibody prevents infection by hepatitis C virus
2. Mass Biologic Labs/UMass Med School and Medarex license C. difficile monoclonal antibody to Merck
3. Antibody key to treating variant CJD, scientists find
4. UC San Diego and Genentech scientists develop potentially disruptive antibody sequencing technology
5. ETH Zurich researchers develop antibody test
6. Bright lights: Mystery of glowing antibody solved by Scripps research scientists
7. Yale chemist receives NIH Young Investigator Award for antibody targeting
8. Reversing cognitive deficits: Injectable antibody may attack source of problem
9. Fossil fragments reveal 500-million-year-old monster predator
10. The song doesnt remain the same in fragmented bird populations
11. EMBL scientists develop first fully automated pipeline for multiprotein complex production
Post Your Comments:
*Name:
*Comment:
*Email: